$1.06
1.39% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US04301G2012
Symbol
ARTL

Artelo Biosciences Inc Stock price

$1.06
+0.03 2.91% 1M
-0.24 18.62% 6M
-0.34 24.29% YTD
-0.28 20.91% 1Y
-7.72 87.92% 3Y
-41.99 97.54% 5Y
-68.69 98.48% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.01 1.39%
ISIN
US04301G2012
Symbol
ARTL

Key metrics

Market capitalization $3.42m
Enterprise Value $-1.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.16
P/B ratio (TTM) P/B ratio 0.54
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-9.54m
Free Cash Flow (TTM) Free Cash Flow $-8.36m
Cash position $4.86m
EPS (TTM) EPS $-2.84
P/E forward negative
Short interest 0.62%
Show more

Is Artelo Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Artelo Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Artelo Biosciences Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Artelo Biosciences Inc forecast:

Buy
100%

Financial data from Artelo Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.90 3.90
20% 20%
-
- Research and Development Expense 5.64 5.64
6% 6%
-
-9.54 -9.54
6% 6%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.54 -9.54
6% 6%
-
Net Profit -9.12 -9.12
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Artelo Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Artelo Biosciences Inc Stock News

Neutral
GlobeNewsWire
20 days ago
Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having st...
Neutral
GlobeNewsWire
about one month ago
SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological and neurological conditions, today announced that Professor Saoirse O'Sullivan, Vice President of Translational Sciences at Artelo, will be...
Neutral
GlobeNewsWire
about 2 months ago
ART26.12, the Company's Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain Studies ART26.12, the Company's Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain Studies
More Artelo Biosciences Inc News

Company Profile

Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.

Head office United States
CEO Gregory Gorgas
Employees 6
Founded 2011
Website www.artelobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today